Type 2 Diabetes

The potential link between GLP-1 therapies and atrial fibrillation is drawing increasing clinical interest as cardiometabolic care continues to evolve. Patients with type 2 diabetes face a significantly higher risk of atrial fibrillation, yet GLP-1 receptor agonists are rarely discussed in rhythm management conversations. Could medications such as semaglutide (Ozempic), …

Continuous glucose monitoring was once reserved for endocrinology clinics. Today, integrating CGM into primary care is essential as guidelines recommend earlier and broader use in both type 1 and type 2 diabetes. Yet many clinicians still feel unsure about how to interpret reports or fit CGM into a busy visit. …

Oral GLP-1 therapy is quickly reshaping how we treat type 2 diabetes, especially for patients who hesitate at the thought of injections. For years, glucagon-like peptide-1 receptor agonists were only available as injectables such as semaglutide and dulaglutide. However, the introduction of semaglutide tablets and the development of higher-dose oral …

GLP-1 receptor agonists have transformed type 2 diabetes care, improving glycemic control, supporting weight loss, and reducing cardiovascular risk. However, disparities in GLP-1 use and access are becoming harder to ignore. Why do some patients gain access quickly while others face barriers at every step? Data suggest that prescribing patterns …

GLP-1 receptor agonists are transforming diabetes and obesity care. However, as more women of reproductive age use medications like semaglutide, liraglutide, and tirzepatide, questions about how GLP-1 therapies affect fertility and pregnancy are becoming increasingly common. Can patients conceive safely while taking these agents? Do they improve ovulation in women …

GLP-1 receptor agonists have transformed type 2 diabetes care. Yet for many patients, gastrointestinal side effects from GLP-1 therapy, such as nausea, vomiting, and constipation, can threaten long-term adherence. Have you ever had a patient achieve an impressive A1C reduction but consider stopping therapy because of persistent nausea? You are …

As more patients succeed on GLP-1 therapy, conversations about tapering these medications are becoming increasingly common in metabolic care. When patients reach meaningful goals in weight reduction, A1C improvement, or cardiometabolic risk, clinicians naturally begin asking what comes next. Is it safe to stop treatment? More importantly, can progress be …

For years, GLP-1 receptor agonists have been associated with older adults who already have type 2 diabetes or established cardiovascular disease. However, metabolic dysfunction does not suddenly appear at age 60. In fact, obesity, insulin resistance, and prediabetes often begin decades earlier. That is why conversations around GLP-1 therapy in …

GLP-1 receptor agonists have changed diabetes care faster than almost any therapy in recent history. In many ways, one medication now touches glucose control, weight loss, cardiovascular risk, and even liver health. However, while outcomes have evolved, the typical clinic visit has stayed the same. As a result, clinicians often …

For many patients, antipsychotic medications are life-changing, even life-saving. Yet the same treatments that stabilize mood and thought can quietly drive weight gain, insulin resistance, and rising cardiometabolic risk. Over time, this unintended consequence places patients with serious mental illness at a much higher risk for obesity, type 2 diabetes, …